T1	ANAT 68 91	líquido cefalorraquídeo
#1	AnnotatorNotes T1	C0007806; Cerebrospinal Fluid; Body Substance
T2	DISO 109 128	infección por VIH-1
#2	AnnotatorNotes T2	C2363741; HIV-1 infection; Disease or Syndrome
T3	PROC 141 168	tratamiento antirretroviral
#3	AnnotatorNotes T3	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T4	CHEM 420 433	emtricitabine
#4	AnnotatorNotes T4	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	CHEM 199 208	ritonavir
#5	AnnotatorNotes T5	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T6	CHEM 211 221	lamivudina
#6	AnnotatorNotes T6	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T7	DISO 1065 1068	VHB
#7	AnnotatorNotes T7	C0019163; Hepatitis B; Disease or Syndrome
T8	DISO 260 288	Infección por el virus VIH-1
T9	DISO 345 368	infectados por el VIH-1
#8	AnnotatorNotes T9	C2363741; HIV-1 infection; Disease or Syndrome
T10	CHEM 410 419	tenofovir
#9	AnnotatorNotes T10	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T11	CHEM 438 448	atazanavir
#10	AnnotatorNotes T11	C1145759; atazanavir; Organic Chemical · Pharmacologic Substance
T12	CHEM 464 473	ritonavir
#11	AnnotatorNotes T12	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T13	PROC 383 386	ART
#12	AnnotatorNotes T13	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T14	PROC 541 560	visita de Screening
#13	AnnotatorNotes T14	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T15	CHEM 575 578	RNA
#14	AnnotatorNotes T15	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T16	CHEM 658 667	ritonavir
#15	AnnotatorNotes T16	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T17	CHEM 672 682	lamivudina
#16	AnnotatorNotes T17	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T18	PROC 689 708	visita de Screening
#17	AnnotatorNotes T18	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T19	PROC 826 847	método anticonceptivo
#18	AnnotatorNotes T19	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T20	DISO 961 983	Insuficiencia hepática
#19	AnnotatorNotes T20	C0085605; Liver Failure; Disease or Syndrome | C1306571; Hepatic Insufficiency; Pathologic Function
T21	DISO 1015 1063	Infección crónica por el virus de la hepatitis B
T22	DISO 1073 1089	Tumores malignos
#20	AnnotatorNotes T22	C0006826; Malignant Neoplasms; Neoplastic Process
T23	DISO 1101 1122	Infección Oportunista
#21	AnnotatorNotes T23	C0029118; Opportunistic Infections; Disease or Syndrome
T24	CHEM 1177 1180	ARV
#22	AnnotatorNotes T24	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T25	CHEM 1235 1245	lamivudina
#23	AnnotatorNotes T25	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T26	CHEM 1308 1334	inhibidores de la proteasa
#24	AnnotatorNotes T26	C0033607; Protease Inhibitors; Pharmacologic Substance
T27	CHEM 1428 1436	fármacos
#25	AnnotatorNotes T27	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T28	PROC 1537 1547	bilirubina
T29	CHEM 153 168	antirretroviral
#26	AnnotatorNotes T29	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T30	CHEM 173 183	atazanavir
#27	AnnotatorNotes T30	C1145759; atazanavir; Organic Chemical · Pharmacologic Substance
T31	PROC 565 578	RNA VIH-1 RNA
T32	PROC 731 755	consentimiento informado
#28	AnnotatorNotes T32	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T33	ANAT 975 983	hepática
#29	AnnotatorNotes T33	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T34	DISO 1463 1474	anormalidad
#30	AnnotatorNotes T34	C1704258; Abnormality; Finding
T35	DISO 1247 1255	mutacion
T36	DISO 1267 1277	mutaciones
#31	AnnotatorNotes T36	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T37	PROC 1515 1518	ALT
#32	AnnotatorNotes T37	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T38	PROC 1521 1524	AST
#33	AnnotatorNotes T38	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T39	CHEM 632 642	atazanacir
T40	Date 13 17	2014
T42	LIVB 95 104	pacientes
#34	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	LIVB 277 288	virus VIH-1
#35	AnnotatorNotes T43	C0019704; HIV-1; Virus
T44	LIVB 319 326	Hombres
#36	AnnotatorNotes T44	C0025266; Male population group; Population Group
T45	Age 328 336	>18 años
T46	Duration 504 523	> 1 mes consecutivo
T47	Duration 596 612	al menos 6 meses
T48	LIVB 790 799	pacientes
#37	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Duration 1025 1032	crónica
#38	AnnotatorNotes T49	C0205191; chronic; Temporal Concept
T50	LIVB 1040 1063	virus de la hepatitis B
#39	AnnotatorNotes T50	C0019169; hepatitis B virus; Virus
T51	Observation 1134 1146	Resistencias
#40	AnnotatorNotes T51	C3542449; Drug Resistance Status; Finding
T52	PROC 1194 1203	genotipos
#41	AnnotatorNotes T52	C1285573; Genotype determination; Laboratory Procedure
T53	Neg_cue 1204 1207	sin
T54	Observation 1221 1232	resistencia
#42	AnnotatorNotes T54	C3542449; Drug Resistance Status; Finding
T56	Observation 1290 1301	resistencia
#43	AnnotatorNotes T56	C3542449; Drug Resistance Status; Finding
T57	Spec_cue 1386 1395	riesgo de
T58	Observation 1396 1407	resistencia
#44	AnnotatorNotes T58	C3542449; Drug Resistance Status; Finding
T41	LIVB 363 368	VIH-1
#45	AnnotatorNotes T41	C0019704; HIV-1; Virus
T55	PROC 992 1002	Child-Pugh
#46	AnnotatorNotes T55	C3854424; Child-Pugh-Turcotte score; Laboratory Procedure
T59	LIVB 123 128	VIH-1
#47	AnnotatorNotes T59	C0019704; HIV-1; Virus
T60	LIVB 569 574	VIH-1
#48	AnnotatorNotes T60	C0019704; HIV-1; Virus
T61	CHEM 565 568	RNA
#49	AnnotatorNotes T61	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
A1	Assertion T58 Speculated
A2	Assertion T54 Negated
A3	Assertion T35 Negated
A4	Assertion T36 Negated
A5	Assertion T56 Negated
#50	AnnotatorNotes T8	C2363741; HIV-1 infection; Disease or Syndrome
#51	AnnotatorNotes T39	C1145759; atazanavir; Organic Chemical · Pharmacologic Substance
#52	AnnotatorNotes T31	C4764103; HIV-1 RNA Measurement; Laboratory Procedure
#53	AnnotatorNotes T21	C0524909; Hepatitis B, Chronic; Disease or Syndrome
#54	AnnotatorNotes T35	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#55	AnnotatorNotes T28	C0005437; Bilirubin; Organic Chemical · Biologically Active Substance
T62	Observation 1365 1381	fallo virológico
A6	Status T62 History_of
T63	Observation 46 61	Supresión viral
#56	AnnotatorNotes T63	C3888663; Sustained viral response; Finding
R1	Location_of Arg1:T1 Arg2:T63	
R2	Experiences Arg1:T42 Arg2:T63	
R3	Experiences Arg1:T42 Arg2:T2	
R4	Causes Arg1:T59 Arg2:T2	
R5	Experiences Arg1:T42 Arg2:T3	
R6	Used_for Arg1:T29 Arg2:T3	
R7	Used_for Arg1:T30 Arg2:T3	
R8	Combined_with Arg1:T30 Arg2:T5	
R9	Combined_with Arg1:T5 Arg2:T6	
R10	Causes Arg1:T3 Arg2:T63	
R11	Causes Arg1:T43 Arg2:T8	
R12	Causes Arg1:T41 Arg2:T9	
R13	Has_Age Arg1:T44 Arg2:T45	
R14	Experiences Arg1:T44 Arg2:T9	
T64	Quantifier_or_Qualifier 387 394	estable
#57	AnnotatorNotes T64	C0205360; Stable status; Qualitative Concept
R15	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T64	
R16	Used_for Arg1:T10 Arg2:T13	
R17	Combined_with Arg1:T10 Arg2:T4	
R18	Combined_with Arg1:T4 Arg2:T11	
R19	Combined_with Arg1:T11 Arg2:T12	
R20	Has_Duration_or_Interval Arg1:T10 Arg2:T46	
R21	Has_Duration_or_Interval Arg1:T4 Arg2:T46	
R22	Before Arg1:T13 Arg2:T14	
R23	Has_Duration_or_Interval Arg1:T11 Arg2:T46	
R24	Has_Duration_or_Interval Arg1:T12 Arg2:T46	
T65	Result_or_Value 579 587	<40 c/mL
R25	Has_Result_or_Value Arg1:T31 Arg2:T65	
R26	Overlap Arg1:T31 Arg2:T47	
R27	Before Arg1:T31 Arg2:T39	
R28	Combined_with Arg1:T39 Arg2:T16	
R29	Combined_with Arg1:T16 Arg2:T17	
R30	Overlap Arg1:T31 Arg2:T18	
T66	CONC 773 782	inclusión
#58	AnnotatorNotes T66	C1512693; Inclusion; Qualitative Concept
R31	Before Arg1:T32 Arg2:T66	
R32	Experiences Arg1:T48 Arg2:T19	
T67	Quantifier_or_Qualifier 848 866	altamente efectivo
R33	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T67	
T68	Observation 874 899	relaciones heterosexuales
#59	AnnotatorNotes T68	C0556476; Heterosexual relationship; Finding
R34	Experiences Arg1:T48 Arg2:T68	
R35	Overlap Arg1:T19 Arg2:T68	
R36	Before Arg1:T18 Arg2:T39	
R37	Location_of Arg1:T33 Arg2:T20	
T69	Result_or_Value 1003 1010	Class C
R38	Has_Result_or_Value Arg1:T55 Arg2:T69	
T70	Quantifier_or_Qualifier 984 990	severa
#60	AnnotatorNotes T70	C1547227; Severe -Severity of Illness Code; Intellectual Product
R39	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T70	
R40	Has_Duration_or_Interval Arg1:T21 Arg2:T49	
R41	Has_Duration_or_Interval Arg1:T7 Arg2:T49	
R42	Causes Arg1:T50 Arg2:T21	
R43	Causes Arg1:T50 Arg2:T7	
T71	Quantifier_or_Qualifier 1090 1097	activos
#61	AnnotatorNotes T71	C0679217; Active State; Idea or Concept
R44	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T71	
T72	Quantifier_or_Qualifier 1123 1129	activa
#62	AnnotatorNotes T72	C0679217; Active State; Idea or Concept
R45	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T72	
R46	Overlap Arg1:T51 Arg2:T24	
T73	Quantifier_or_Qualifier 1147 1156	primarias
#63	AnnotatorNotes T73	C0205225; Primary; Qualitative Concept
R47	Has_Quantifier_or_Qualifier Arg1:T51 Arg2:T73	
R48	Negation Arg1:T53 Arg2:T54	
R49	Overlap Arg1:T54 Arg2:T25	
T74	Quantifier_or_Qualifier 1256 1263	M184V/I
R50	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T74	
R51	Negation Arg1:T53 Arg2:T35	
A7	Assertion T74 Negated
R52	Negation Arg1:T53 Arg2:T74	
R53	Overlap Arg1:T36 Arg2:T56	
R54	Overlap Arg1:T56 Arg2:T26	
R55	Negation Arg1:T53 Arg2:T36	
R56	Negation Arg1:T53 Arg2:T56	
R57	Speculation Arg1:T57 Arg2:T58	
R58	Before Arg1:T62 Arg2:T58	
R59	Overlap Arg1:T58 Arg2:T27	
R60	Overlap Arg1:T62 Arg2:T27	
T75	Quantifier_or_Qualifier 1489 1496	grado 4
T76	Observation 1463 1474;1497 1511	anormalidad de laboratorio
#64	AnnotatorNotes T76	C3648370; laboratory tests nonspecific abnormal findings; Finding
R61	Has_Quantifier_or_Qualifier Arg1:T76 Arg2:T75	
T77	Result_or_Value 1525 1532	≥ 3xLSN
R62	Has_Result_or_Value Arg1:T38 Arg2:T77	
R63	Has_Result_or_Value Arg1:T37 Arg2:T77	
T78	Result_or_Value 1548 1557	≥ 1.5xLSN
R64	Has_Result_or_Value Arg1:T28 Arg2:T78	
#65	AnnotatorNotes T62	C4053865; Virologic Non-Response; Finding (?)
A8	Experiencer T42 Patient
A9	Experiencer T44 Patient
A10	Experiencer T48 Patient
